Precigen Strategically Prioritizes Portfolio To Focus On First Potential Gene Therapy Launch, Including A Reduction Of Over 20% Of Its Workforce
Portfolio Pulse from Benzinga Newsdesk
Precigen, Inc. (NASDAQ:PGEN) is strategically prioritizing its portfolio to focus on the potential launch of its gene therapy, PRGN-2012, for recurrent respiratory papillomatosis (RRP). The company is reducing its workforce by over 20% and has initiated patient enrollment in a confirmatory clinical trial for PRGN-2012, which is on track for a rolling BLA submission under an accelerated approval pathway.
August 06, 2024 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precigen is focusing on the potential launch of its PRGN-2012 gene therapy for RRP, reducing its workforce by over 20%, and initiating patient enrollment in a confirmatory clinical trial. The PRGN-2012 is on track for a rolling BLA submission under an accelerated approval pathway.
The strategic focus on PRGN-2012 and the workforce reduction indicate a strong commitment to bringing this therapy to market, which could positively impact the stock price. The initiation of patient enrollment and the accelerated approval pathway further support a positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100